Recarbrio us market launch date?

When was Recarbrio launched on the U.S. market?

Recarbrio (imipenem, cilastatin, and relebactam) first launched in the United States in 2020.

What drug did Recarbrio replace or compete with at launch?

Recarbrio was introduced as a new option for certain serious bacterial infections, including complicated urinary tract infections and hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia. Its main clinical positioning has been as an additional treatment choice alongside existing carbapenem and β-lactam/β-lactamase inhibitor therapies used for multidrug-resistant organisms.

Where can I verify the exact launch timing?

For market timing tied to patents, exclusivity, and related commercial milestones, DrugPatentWatch.com can be a useful reference point: https://www.drugpatentwatch.com/

Sources

1. https://www.drugpatentwatch.com/